Meeting Coverage

ESMO: CDK4/6 inhibitor palbociclib effective in ER+ advanced endometrial cancer

Sep 24, 2020

No standard treatment has been defined yet for second- or third-line systemic treatment of...

ESMO: Is adding an immune checkpoint inhibitor to targeted therapy the right approach?

Sep 24, 2020

According the primary results of the COMBI-i trial, the addition of PD1 inhibitor spartalizumab to...

ESMO: Immunotherapy Improves Gastric Cancer Outcomes

Sep 23, 2020

Addition to chemotherapy may set a new Standard Immunotherapy for patients with high-risk gastric and esophageal cancers appears to control the diseases better than standard of care chemotherapy, researchers suggested at the...

ECTRIMS-ACTRIMS 2020 Late Breaking News: Encore Session, Sept 26th

Sep 22, 2020

The 8th Joint ACTRIMS-ECTRIMS meeting – the largest international conference focused on research...

PhysQuiz Answers! ACR Convergence 2020

Sep 19, 2020

Thank you for taking our quiz on PsA from results presented at ACR Convergence 2020! How did you do? 1) DMARD-naïve patients achieving Routine Assessment of Patient Index Data 3 (RAPID3) and the Clinical Disease Activity for...

ESMO Virtual Congress 2020 Around the Corner: All Eyes On Lung Cancer

Sep 17, 2020

The ESMO Virtual Congress 2020, September 19-21, will present promising new developments aimed at...

ESMO 2020: Tumor-Agnostic Data from STARTRK-1 and STARTRK-2

Sep 17, 2020

Two sets of CNS efficacy data from integrated analyses of the pivotal phase II STARTRK-2, phase I STARTRK-1, and phase I ALKA-372-001 trials will be presented, including a poster presentation evaluating the efficacy of...

ESMO 2020: Analysis of Long-Term Survivors in the IMpower133 Trial for ES-SCLC

Sep 17, 2020

Results from an exploratory analysis of characterization of long-term survivors (LTS), defined in the study as people who survived for longer than 18 months following randomization, in the IMpower133 trial will be presented in a...

ACTRIMS-ECTRIMS: Thyroid Disorders Don’t Affect MS Control

Sep 17, 2020

Thyroid AEs did not diminish alemtuzumab efficacy Adverse thyroid events occur frequently among relapsing-remitting multiple sclerosis patients, but the vast majority of those events occur early in the course of treatment and...

ACTRIMS-ECTRIMS: Advantages Seen for Ozanimod over Teriflunomide

Sep 17, 2020

Safety modeling favors ozanimod Patients diagnosed with multiple sclerosis appear to have fewer...

Final Data From Phase 1b FORWARD II Triplet Cohort Evaluating Mirvetuximab Soravtansine in Combination With Carboplatin and Bevacizumab

Sep 17, 2020

final data from the FORWARD II triplet cohort evaluating mirvetuximab soravtansine in combination with carboplatin and bevacizumab (Avastin® )in patients with folate receptor alpha (FRα)-positive recurrent, platinum-sensitive...